Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon

Institut de Recherche pour le Développement, University Montpellier 1, UMR 145, Montpellier, France.
BMC Public Health (Impact Factor: 2.26). 03/2010; 10(1):105. DOI: 10.1186/1471-2458-10-105
Source: PubMed


Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment. We compared the hepatotoxicity and the immunological, virological and clinical effectiveness of a nevirapine-based antiretroviral therapy between patients infected with HIV only and patients coinfected with hepatitis B or C virus in Cameroon.
A retrospective cohort study was conducted among HIV-1-infected patients. Plasma HBV DNA and HCV RNA were tested in positive or indeterminate samples for HBsAg or HCV antibodies, respectively. All patients received nevirapine and lamivudine plus stavudine or zidovudine.
Of 169 HIV-1-infected patients with a median baseline CD4 count of 135 cells/mm3 (interquartile range [IQR] 67-218), 21% were coinfected with HBV or HCV. In coinfected patients, the median viral load was 2.47 x 107 IU/mL for HBV (IQR 3680-1.59 x 108) and 928 000 IU/mL for HCV (IQR 178 400-2.06 x 106). Multivariate analyses showed that the risk of hepatotoxicity was 2-fold higher in coinfected patients (p < 0.01). The response to antiretroviral therapy was however comparable between monoinfected and coinfected patients in terms of CD4 cell count increase (p = 0.8), HIV-1 viral load below 400 copies/mL (p = 0.9), death (p = 0.3) and death or new AIDS-defining event (p = 0.1). Nevirapine was replaced by a protease inhibitor in 4 patients owing to hepatotoxicity.
This study suggests that the nevirapine-based antiretroviral therapy could be used safely as first-line treatment in patients with low CD4 cell count in Africa despite frequent coinfections with HBV or HCV and infrequent testing of these infections. Although testing for HBV and HCV should be systematically performed before initiating antiretroviral therapy, transaminases elevations at baseline or during treatment should be a decisive argument for testing when hepatitis status is unknown.

Download full-text


Available from: Henri Gwét,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liver enzyme elevations among patients on antiretroviral therapy (ART) were determined by prospectively evaluating aspartate aminotransferase (AST) data in a cohort of patients in Kampala over 36 months. A proportion of patients had hepatitis B virus (HBV) status determined. Hepatotoxicity was graded I to IV according to the AIDS Clinical Trial Group criteria. Of 546 patients, 377 (69%) were women; overall median baseline CD4+ T-cell was 97/μL (interquartile range [IQR] 20-164). Hepatitis B surface antigen (HBsAg) was detected in 42 (9%) of 470 persons. ART included lamivudine, with either nevirapine and d4T (74%) or efavirenz and AZT (26%). Median (IQR) AST level at baseline was 35 (27, 53 IU/L). Over 36 months, only eight patients had grade III AST elevation. Neither HBsAg nor ART regimen influenced AST levels. Male gender and CD4+ change from baseline were correlated with AST elevation. Patients with HIV/HBV co-infection were not at an increased risk of AST elevation, which occurred uncommonly in this setting.
    International Journal of STD & AIDS 08/2010; 21(8):553-7. DOI:10.1258/ijsa.2010.010027 · 1.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver disease in human immunodeficiency virus (HIV)-infected individuals encompasses the spectrum from abnormal liver function tests, liver decompensation, with and without evidence of cirrhosis on biopsy, to non-alcoholic liver disease and its more severe form, non-alcoholic steatohepatitis and hepatocellular cancer. HIV can infect multiple cells in the liver, leading to enhanced intrahepatic apoptosis, activation and fibrosis. HIV can also alter gastro-intestinal tract permeability, leading to increased levels of circulating lipopolysaccharide that may have an impact on liver function. This review focuses on recent changes in the epidemiology, pathogenesis and clinical presentation of liver disease in HIV-infected patients, in the absence of co-infection with hepatitis B virus or hepatitis C virus, with a specific focus on issues relevant to low and middle income countries.
    World Journal of Hepatology 03/2012; 4(3):91-8. DOI:10.4254/wjh.v4.i3.91
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nevirapine was the first nonnucleoside reverse transcriptase inhibitor that was approved for treatment of HIV infection and quickly became an important component of HAART. As experience with this drug grew, potential toxicities and significant clinical benefits became apparent. With the development of new patient criteria based on CD4(+) cell counts, new treatment initiation guidelines were developed. Incorporation of these criteria has reduced the incidence of rare but significant toxicities associated with nevirapine therapy to levels seen with other drugs. For treatment-naive patients who meet established starting criteria, or for patients switching from other nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based regimens, nevirapine can offer potent and durable viral suppression with significant clinical benefits. These benefits include the absence of central nervous system effects in patients who are at risk for depression, minimal untoward effects on serum lipid profiles, which is especially important for patients who have other cardiovascular disease risk factors, and relative safety during pregnancy for women of childbearing age. Patients who should avoid nevirapine include those with prior hypersensitivity reactions, those who do not meet treatment initiation criteria, those who experience adverse reactions during induction, and those with existing hepatotoxicity. This review focuses on current information regarding the role of nevirapine in HAART and defines patient groups whose clinical profiles may warrant consideration of nevirapine.
    AIDS reviews 04/2012; 14(2):132-44. · 3.79 Impact Factor
Show more